deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT06941688

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Phase II, Multicentre, Randomized Study of Decitabine Plus GemOx Versus GemOx for Relapsed/Refractory Peripheral T-cell Lymphoma

Sponsor: Seoul National University Hospital

Conditions Peripheral T-cell Lymphoma (PTCL)
Interventions Decitabine with GemOx GemOx
Updated 2 times since 2025 Last updated: Apr 22, 2025 Started: Nov 13, 2020 Primary completion: Aug 13, 2024 Completion: Dec 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow recruitment

Other terminated trials from Seoul National University Hospital

See all terminations from Seoul National University Hospital

This PHASE2 trial investigates Peripheral T-cell Lymphoma (PTCL) and is currently terminated or withdrawn. Seoul National University Hospital leads this study, which shows 2 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2025 – ~Sep 2025 · 4 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Seoul National University Hospital
Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations